The Toronto Stock Exchange reports that Profound Medical Corp. will be listed and posted for trading on the TSX at the open on July 13, 2018. According to the TSX, there will be 108,043,939 shares of the company issued and outstanding, and 36,295,712 shares reserved for issuance. The shares will trade under the symbol PRN and Cusip No. 74319B 10 6.
The TSX reports that Profound is a medical device technology company developing a treatment to ablate the prostate gland in prostate cancer patients, a treatment of uterine fibroids, and a palliative treatment of bone metastases. According to the TSX, the company does not expect to pay dividends in the foreseeable future. Profound's transfer agent and registrar is TSX Trust Company at its principal office in Toronto, and its fiscal year-end is Dec. 31.
The TSX notes that Profound's shares have been listed on the TSX Venture Exchange since Sept. 24, 2014, under the symbol PRN. The shares will be delisted from the TSX-V upon the start of trading on the TSX.
© 2019 Canjex Publishing Ltd. All rights reserved.